Award Winners




MS International Foundation Award for Best presentation of a translational project in the young intevestigator's session

YI2.6 VLA-4 blockade promotes differential routes into human CNS involving PSGL-1-rolling of T-cells and MCAM-adhesion of TH17-cells
T Schneider-Hohendorf1, J Rossaint2, J Breuer1, A Zarbock2, N Schwab1, H Wiendl1
1University of Muenster, Neurology, Muenster, Germany, 2University of Muenster, Anaesthesiology, Muenster, Germany


MSBoston 2014 Young Investigator for Oral Presentations

FC3.4  Treatment with cyclic oral methylprednisolone in progressive multiple sclerosis-results of an open-label phase 2A proof-of-concept study
R Ratzer1, J Romme Christensen1, L Börnsen1, C Ammitzbøll1, P Iversen2, TB Dyrby2, HR Siebner2, C Gøbel Madsen2, E Garde2, B Andersen3, L Hyldstrup4, PS Sørensen1, F Sellebjerg1
1Rigshospitalet, Neurology, Copenhagen, Denmark, 2Hvidovre Hospital, Danish Research Center for Magnetic Resonance, Hvidovre, Denmark, 3Rigshospitalet, Neurophysiology, Copenhagen, Denmark, 4Hvidovre Hospital, Endocrinology, Hvidovre, Denmark

PS4.4  In vivo administration of Clostridium perfringens epsilon toxin targets cells associated with multiple sclerosis
J Linden1, KR Rumah1, T Vartanian1
1Weill Cornell Medical College, New York, NY, United States


MSBoston 2014 Best Poster Presentation

P374 The CNS barriers differentially regulate the migration of B cells
L Michel1, JI Alvarez1, H Kebir1, L Bourbonnière1, J Poirier2, P Duquette2, A Bar-Or3, J Gommerman4, A Prat1,2 
1CRCHUM, Neurosciences, Montréal, QC, Canada, 2Notre Dame Hospital, Neurology, Montréal, QC, Canada, 3Mc Gill University, Neurology and Neurosurgery, Montréal, QC, Canada, 4Toronto University, Immunology, Toronto, ON, Canada

P376 Serpine1 is a negative regulator of experimental autoimmune encephalomyelitis
M Rangachari1, N Boivin1, A Chen2, C Zhu3, VK Kuchroo3
1Centre de Recherche du CHU de Québec, Quebec, QC, Canada, 2Stony Brook School of Medicine, Stony Brook, NY, United States, 3Brigham & Women’s Hospital, Boston, MA, United States

P557 Epigenetic changes in CD8+ T cells and CD19+ B cells isolated from relapsing/remitting multiple sclerosis patients
MC Graves1, M Benton2, R Lea1, D Macartney3, L Tajouri4, RJ Scott1, J Lechner-Scott5
1Hunter Medical Research Institute, Molecular Genetics, Newcastle, Australia, 2Griffith University, Brisbane, Australia, 3Institute of Environmental Science and Research, Porirua, New Zealand, 4Bond University, Gold Coast, Australia, 5John Hunter Hospital, Neurology, Newcastle, Australia

P758Maximal lifetime brain growth (estimated with intracranial volume) is linked to level of disability on the Multiple Sclerosis Functional Composite
JF Sumowski1, CS Riley2, G Tosto2, VM Leavitt3
1Kessler Foundation, West Orange, NJ, United States, 2Columbia University Medical Center, New York, NY, United States, 3Manhattan Memory Center, New York, NY, United States

P330In utero 25-hydroxyvitamin D and risk of multiple sclerosis among offspring in the Finnish Maternity Cohort
K Munger1, M Soilu-Hänninen2, J Åivo2, K Hongell2, H-M Surcel3, A Ascherio1
1Harvard School of Public Health, Boston, MA, United States, 2University Hospital of Turku, Turku, Finland, 3National Institute for Health and Welfare, Oulu, Finland


MS Journal Award for abstract that reports work that most contributes to the treatment of management of MS and related diseases

PS2.5 Autoantibodies against MOG and Aquaporin-4 Identify Distinct Neuromyelitis Optica Spectrum Disorders Subgroups 
DK Sato1, D Callegaro2, MA Lana-Peixoto3, PJ Waters4, S Tanaka5, FMH Jorge2, T Takahashi1, T Misu6, SL Apostolos- Pereira2, N Talim3, RF Simm2, I Nakashima1, K Nomura5, M Aoki1, K Fujihara6
1Tohoku University, Neurology, Sendai, Japan, 2University of Sao Paulo, Neurology, São Paulo, Brazil, 3Federal University of Minas Gerais, CIEM MS Research Center, Belo Horizonte, Brazil, 4Oxford University, Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom, 5Saitama Medical University, Neurology, Saitama, Japan, 6Tohoku University, Multiple Sclerosis Therapeutics, Sendai, Japan


MS Journal Award for abstract that reports work that most contributes to the treatment or management of MS and related diseases

PS9.4 Factors that determine disease course: early changes contribute to predict long-term prognosis, the “Barcelona inception cohort"
M Tintoré1, Á Rovira2, S Otero-Romero1,3, G Arrambide1, C Tur1, M Comabella1, C Nos1, M-J Arévalo1, L Negrotto1, I Galán1, À Vidal-Jordana1, J Castilló1, F Palavra1, E Simón1, R Mitjana2, C Auger2, J Sastre-Garriga1, X Montalban1
1Vall Hebron University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona, Spain, 2Vall Hebron University Hospital, Magnetic Resonance Unit, Neuroradiology Department, Barcelona, Spain, 3Vall Hebron University Hospital, Preventive Medicine and Epidemiology Department, Barcelona, Spain



For more information on the program, support opportunities, or any general questions, please contact the ACTRIMS Secretariat.

22 North Carroll Street, Suite 300
Madison, Wisconsin 53703 USA

+ 1 608 310 8960

Logistics Secretariat

For more information about housing, registration, press, media and Boston in general, please contact the Logistics Secretariat.

c/o Opus 3 inc.
417 Saint-Pierre Street, Suite 302
Montréal QC H2Y 2M4 Canada

+ 1 514 395 1808

opus logo